HCW9218 for Advanced Pancreatic Cancer

A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-β (Transforming Growth Factor Beta) Antagonist/IL-15 (Interleukins) Protein Complex, for Advanced Pancreatic Cancer

This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.

Study Overview

• Status: Completed
• Conditions: Advanced Pancreatic Carcinoma
• Intervention / Treatment: Drug: HCW9218; Drug: Gemcitabine (GEM); Drug: Nab-paclitaxel

Detailed Description

The study involves a Phase 1b dose escalation portion with up to 30 patients to determine the MTD (maximum tolerated dose) using a 3+3 dose escalation design and to designate a dose level for the Phase 2 expansion phase (RP2D).

The Phase 2 portion of the study will consist of an expansion cohort of up to 39 patients receiving HCW9218 monotherapy at the RP2D level. An additional independent Phase 2 cohort of patients receiving HCW9218 at the RP2D level in sequence with gemcitabine and nab-paclitaxel will also be considered.

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85258
      • HonorHealth
  • Maryland
    • Bethesda, Maryland, United States, 20892
      • National Institute of Health/ National Cancer Institute
  • Missouri
    • St Louis, Missouri, United States, 63110
      • Washington University in St. Louis
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Medical University of South Carolina

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

Subjects must meet all of the following criteria for inclusion in the study (to be verified by Sponsor prior to subject enrollment):

1. Histologically or cytologically confirmed unresectable, advanced/metastatic disease pancreatic cancer that has progressed on standard first-line (or second- or later line) systemic therapy (excepting progression within 6 months of end of adjuvant systemic chemotherapy); or that can no longer be treated with first-line systemic therapy due to subject's intolerance.
2. For dose escalation phase (Phase 1b), distant metastatic disease or advanced disease and not a candidate for down staging to resection For expansion phase (Phase 2), distant metastatic disease only
3. Measurable disease by CT, MRI, PET-CT (Positron Emission Tomography) or other methods described in Section 7.2., as assessed by RECIST v1.1.
4. Prior radiation is allowed if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment. Radiation therapy must have been completed at least 4 weeks prior to the baseline scan.
5. Resolved acute effects of any prior therapy to baseline or Grade ≤ 1 NCI CTCAE v5.0 except for AEs not constituting a safety risk by Investigator judgment.
6. Age > 18 years
7. Performance status: ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1 or 2 (Section 20.2).
8. A life expectancy of at least 12 weeks.

9. Laboratory tests performed within 14 days of treatment start:

   1. Absolute neutrophil count (AGC/ANC) ≥ 1,500/μL (≥1.5 × 109/L)
   2. Platelets ≥ 100,000/μL (≥ 100 × 109/L) [Subjects may be transfused not more than 1 unit of platelets within 2 weeks to meet this requirement]
   3. Hemoglobin ≥ 9 g/dL (>90g/L) [Subjects may be transfused not more than 2 units of pRBCs (packed red blood cell) within 2 weeks to meet this requirement]
   4. Calculated glomerular filtration rate (GFR)* >40 mL/min OR serum creatinine ≤ 1.5 × ULN (upper limit of normal)
   5. Total bilirubin ≤ 2.0 × ULN (upper limit of normal) or ≤ 3.0 × ULN (upper limit of normal) for subjects with Gilbert's syndrome
   6. AST (aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase) ≤ 2.5 × ULN (upper limit of normal) or ≤ 5.0 × ULN (upper limit of normal) if liver metastasis present *using the following Cockcroft & Gault equation to calculate the eGFR (epidermal growth factor receptor) for this study. eGFR (epidermal growth factor receptor) in mL/min = [(140-age in years) × (weight in kg) × F]/(serum creatinine in mg/dL × 72), where F =1 if male; and 0.85 for female.
10. Adequate pulmonary function with PFTs (Pulmonary Function Test) > 50% FEV1 (forced expiratory volume at one second) if symptomatic or prior known impairment.
11. Negative serum pregnancy test within 14 days of treatment start if female and of childbearing potential (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized).
12. Female subjects of childbearing potential must adhere to using a medically accepted method of birth control prior to screening and agree to continue its use for at least 28 days after the last dose of HCW9218 or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use a barrier method of birth control and agree to continue its use for at least 28 days after the last dose of HCW9218.
13. Provide signed informed consent and HIPAA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations.

Exclusion Criteria

Subjects with any of the following criteria are excluded from participation in the study (to be verified by Sponsor prior to subject enrollment):

1. History of clinically significant vascular disease, including any of the following within 6 months prior to start of study treatment: MI (myocardial infarction) or unstable angina, percutaneous coronary intervention, bypass grafting, ventricular arrhythmia requiring medication, stroke or transient ischemic attack, symptomatic peripheral arterial disease.
2. Marked baseline prolongation of QT/QTc interval (corrected QT interval) (e.g., demonstration of a QTc interval (corrected QT interval) greater than or equal to 470 milliseconds by Fridericia's correction).
3. Subjects with untreated CNS (Central Nervous System) metastases are excluded. Subjects are eligible if CNS (Central Nervous System) metastases are treated and subjects are neurologically stable for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroid, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent).
4. Anti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days before treatment start.
5. Other prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the subject is currently in complete remission, or any other cancer from which the subject has been disease-free for 3 years after surgery treatment.
6. Known hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study.
7. Prior therapy with TGF-β (Transforming Growth Factor Beta) antagonist, IL-15 (interleukin-15) or analogs.
8. Concurrent herbal or unconventional therapy (e.g., St. John's Wort)
9. Known autoimmune disease requiring active treatment. Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
10. Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
11. Prior organ allograft or allogeneic transplantation
12. Known HIV-positive or AIDS
13. Women who are pregnant or nursing
14. Any ongoing toxicity from prior anti-cancer treatment that, in the judgment of the Investigator may interfere with study treatment. All toxicities attributed to prior anti-cancer therapy other than peripheral neuropathy, alopecia, and fatigue must resolve to grade 1 (NCI CTCAE v5.0) or baseline before administration of the study treatment.
15. Psychiatric illness/social situations that would limit compliance with study Requirements.
16. Other illness or a medical issue that in the opinion of the Investigator would exclude the subject from participating in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: HCW9218; Experimental Arm: HCW9218

Drug: HCW9218; Bifunctional TGF-β (Transforming Growth Factor Beta) antagonist/IL-15 (Interleukin-15) protein complex; Drug: Gemcitabine (GEM); Gemcitabine is administered as a combination chemotherapy regimen for the treatment of advanced/metastatic pancreatic cancer in accordance with standard-of-care dosing and schedule per protocol; Drug: Nab-paclitaxel; Nab-paclitaxel is administered as a combination chemotherapy regimen for the treatment of advanced/metastatic pancreatic cancer in accordance with standard-of-care dosing and schedule per protocol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of Adverse Events and Treatment-Related Adverse Events	Evaluate the safety profile (as outlined by incidence of adverse events (AEs) based on CTCAE v5) of HCW9218 monotherapy in subjects with advanced/metastatic pancreatic cancer who have progressed on or are intolerant of standard first-line therapy	12 Months
Determine the maximum tolerated dose (MTD)	Determine the maximum tolerated dose (MTD) and designate the recommended Phase 2 dose level (RP2D) for Phase 2 study of HCW9218 in HCW9218-treated subjects	12 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	To evaluate objective response rate (ORR) per RECIST version 1.1	12 Months
Progression-Free Survival (PFS)	To assess the progression-free survival (PFS) per RECIST version 1.1	12 Months
Overall Survival (OS)	OS is defined as the time from first administration of study intervention to the date of death due to any cause.	12 Months
Duration of Response	Duration of response is the time from response to progression or death.	12 Months

Collaborators and Investigators

• Sponsor: ImmunityBio, Inc.
• Investigators: Study Director: Paula Bradshaw, MSN, MBA, RN, VP, Clinical Business Operations

Study record dates

Study Major Dates

• Study Start (Actual): October 17, 2022
• Primary Completion (Actual): February 15, 2025
• Study Completion (Actual): February 15, 2025

Study Registration Dates

• First Submitted: March 11, 2022
• First Submitted That Met QC Criteria: March 22, 2022
• First Posted (Actual): March 31, 2022

Study Record Updates

• Last Update Posted (Actual): April 15, 2026
• Last Update Submitted That Met QC Criteria: April 10, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Neoplasms by Site; Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Gemcitabine; 130-nm albumin-bound paclitaxel
• Other Study ID Numbers: HCWPAN102

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No